On July 6, 2023 Shorla Oncology (‘Shorla’), a U.S.-Ireland pharmaceutical company, reported that it has entered into a licensing agreement and strategic partnership with a U.K.-based innovative drug development and manufacturing company (Press release, Shorla Oncology, JUL 6, 2023, View Source [SID1234633088]). Under the terms of the agreement, Shorla will obtain an exclusive license from the developer to register and commercialize PIP-101, the first palatable oral solution of the related chemotherapeutic agent in the U.S.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

PIP-101 is an oral solution treatment that slows or stops the growth of certain forms of leukemia, such as acute lymphoblastic leukemia and chronic myeloid leukemia.

"We are excited to partner with and leverage the developer’s oral oncology liquid manufacturing expertise," said Sharon Cunningham, CEO and Co-founder of Shorla Oncology. "This commercial partnership is a strong endorsement of our commitment to bring to market differentiated oncology treatments to address key areas of unmet needs for patients."

Under the terms of the agreement, the developer will continue to manufacture PIP-101. Once Shorla has obtained approval of its New Drug Application (NDA), the company will be responsible for the timely launch, commercialization and sales of PIP-101 in the U.S.

"We look forward to a long-term relationship with the developer with not only PIP-101, but other treatments that are in the pipeline," said Orlaith Ryan, CTO and co-founder of Shorla Oncology. "We expect this partnership will take both companies to new heights and provide much-needed oncology treatments to patients with cancer."

The U.S. Food and Drug Administration recently approved Shorla Oncology’s Nelarabine Injection for the treatment of T-cell Leukemia, an aggressive blood and bone marrow cancer. Shorla also has plans to have three products on market and three or more in development by end of year 2024.